Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: valproic acid Clear all
Completed Not applicable Interventional

Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability

NCT00347152
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

NCT00246103
View directory record Official record
Conditions
Neoplasms, Advanced
Interventions
Valproic acid, Epirubicin, 5-fluorouracil, Cyclophosphamide.
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

NCT00195780
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Divalproex Sodium (Depakote ER)
Drug
Lead sponsor
Abbott
Industry
Eligibility
10 Years to 17 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
29
States / cities
San Diego, California • San Marcos, California • Altamonte Springs, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2007 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients

NCT00581009
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
Other · Drug · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2011
U.S. locations
2
States / cities
Irvine, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population

NCT00207935
View directory record Official record
Conditions
Epilepsy, Mental Retardation, Developmental Disabilities
Interventions
Swallow instruction
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2008 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Early Phase 1 Interventional

Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

NCT01738815
View directory record Official record
Conditions
Hematuria, Bladder Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania

NCT00206778
View directory record Official record
Conditions
Mixed Mania Bipolar Disorder
Interventions
Lamotrigine, Sodium Valproate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

NCT00530907
View directory record Official record
Conditions
Advanced Cancer
Interventions
Valproic Acid, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

NCT00195754
View directory record Official record
Conditions
Migraines
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2007 · Synced Sep 3, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer

NCT00525135
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 3, 2026, 5:46 PM EDT
Not listed Phase 1 Interventional

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

NCT00197834
View directory record Official record
Conditions
Dementia
Interventions
Depakote
Drug
Lead sponsor
Hearthstone Alzheimer Care
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

NCT00075010
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Valproic acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 3, 2026, 5:46 PM EDT
Terminated Phase 4 Interventional

Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder

NCT00203385
View directory record Official record
Conditions
PTSD
Interventions
Divalproex
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 3, 2026, 5:46 PM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

NCT04531579
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

NCT00278772
View directory record Official record
Conditions
Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania
Interventions
Divalproex, Placebo
Drug · Other
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

12- Week Open Label Treatment of Refractory Bipolar Depression

NCT00223496
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
81
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2008 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

NCT00513162
View directory record Official record
Conditions
Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
Interventions
Valproate, Etoposide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

NCT01106872
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma, Metastatic Sarcoma
Interventions
Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
Drug
Lead sponsor
Mohammed M Milhem
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 3, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder

NCT00221429
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, sodium divalproex, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 3, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

NCT00315900
View directory record Official record
Conditions
Agitation, Dementia
Interventions
Depakote ER, Seroquel
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 3, 2026, 5:46 PM EDT